OSRX Confirms Ongoing Licensing and Availability of Compounded Ophthalmic Medications in California
Harrow Health, Inc. (HROW)
Last harrow health, inc. earnings: 11/13 04:21 pm
Check Earnings Report
Company Research
Source: Business Wire
The Montana-based compounder commits to supporting prescribers and patients in wake of competitor’s abrupt exit of California market MISSOULA, Mont.--(BUSINESS WIRE)--OSRX, Inc., a leading provider of compounded ophthalmic medications, announced that the company remains fully licensed, fully operational and continues to serve the needs of California ophthalmologists and optometrists, following a significant market shift involving a major competitor.According to a Feb. 2, 2026 company disclosure, ImprimisRx – the compounding division of Harrow (NASDAQ:HROW) – voluntarily forfeited its California license on February 1 and agreed to pay an administrative fine of approximately $157,000 as part of a settlement agreement reached with the California Board of Pharmacy (CBOP).1 The CBOP previously filed a formal accusation against ImprimisRx in August 2025 outlining multiple causes for discipline.2This licensing action pertains solely to ImprimisRx and does not affect other 503B outsourcing
Show less
Read more
Impact Snapshot
Event Time:
HROW
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HROW alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HROW alerts
High impacting Harrow Health, Inc. news events
Weekly update
A roundup of the hottest topics
HROW
News
- Harrow (NASDAQ:HROW) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong GrowthGlobeNewswire
- Harrow: Revisiting This Eyecare Growth Story Ahead Of Q4 Update [Seeking Alpha]Seeking Alpha
- Breakeven Is Near for Harrow, Inc. (NASDAQ:HROW) [Yahoo! Finance]Yahoo! Finance
- How CVS Elevating Vevye To Tier 1 Coverage At Harrow (HROW) Has Changed Its Investment Story [Yahoo! Finance]Yahoo! Finance
HROW
Earnings
- 11/10/25 - Beat
HROW
Sec Filings
- 2/2/26 - Form 4
- 2/2/26 - Form 3
- 2/2/26 - Form 8-K
- HROW's page on the SEC website